Key result
Tongguan Capsule (5 g/kg/d) pretreatment significantly reduced infarct size and the incidence of arrhythmias compared with the I/R control group in mice models of myocardial ischemia/reperfusion.
Why the study?
Does Tongguan Capsule pretreatment reduce infarct size and arrhythmias in mice models of myocardial ischemia/reperfusion injury?
Does Tongguan Capsule pretreatment reduce infarct size and arrhythmias in mice models of myocardial ischemia/reperfusion injury?
Tongguan Capsule pretreatment reduces infarct size and the incidence of arrhythmias in a mouse model of myocardial ischemia/reperfusion injury.
Does not support clinical use; leaves open translation of Tongguan Capsule benefits to human ischemia/reperfusion injury.
Myocardial ischemia/reperfusion (I/R) can induce lethal ventricular arrhythmia and myocardial infarction. One of the clinical strategies for managing patients with high risk of myocardial I/R is to prevent the occurrence of arrhythmias and limit the size of infarction following a coronary episode. Tongguan Capsule (TGC) is one of the popular herbal remedies in treating coronary artery disease in the clinics of Chinese medicine. However, the potential roles and mechanisms of TGC in reducing I/R injury are still unclear. The present study statistically assessed the effectiveness of TGC in reducing I/R injury by comparing the infarct size (IS), risk region (RR), and arrhythmia (in electrocardiogram) among four groups of surgically created mice models of myocardial I/R: SHAM, I/R, VER (I/R with verapamil 20 mg/kg pretreatment), and TGC (I/R with TGC 5 g/kg/d pretreatment). We found that IS was significantly smaller in the TGC and VER groups than I/R group, and the incidence of arrhythmias was reduced in the TGC group compared with I/R group, although there were no differences in RR among the four groups. We conclude that TGC is effective in reducing I/R injury in mice. These results provided an experimental basis for clinical application of TGC in reducing I/R injury.
No takes yet. Share an insight, caveat, or question.
Qi et al. (2013) studied Myocardial ischemia/reperfusion injury. Tongguan Capsule vs. I/R control, SHAM, and Verapamil was evaluated on Infarct size, risk region, and arrhythmia. Tongguan Capsule (5 g/kg/d) pretreatment significantly reduced infarct size and the incidence of arrhythmias compared with the I/R control group in mice models of myocardial ischemia/reperfusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: